9 minutes read

China’s head and neck cancer treatment has reached globally leading levels in multiple subspecialties: Nasopharyngeal cancer (NPC) — Sun Yat-sen University Cancer Center (SYSUCC) led 4 of 6 NCCN nasopharyngeal cancer guideline revisions over 20 years [1], and Toripalimab (Chinese domestic PD-1) received FDA approval in 2023 for NPC — the first FDA-approved Chinese PD-1 drug; Shanghai Proton and Heavy-Ion Center (SPHIC) achieves primary NPC 5-year OS of 92.9%; Beijing Tongren Hospital pioneered laryngeal preservation treatment in China; Shanghai 9th People’s Hospital performed 929 microvascular free flap reconstructions in 2018 with >98% success rate; thyroid microcarcinoma (PTMC) radiofrequency ablation (RFA) in Chinese multi-center research achieved 79% complete disappearance rate. Pricing is typically 1/5 to 1/10 of US. This article walks through China’s head and neck cancer treatment capabilities by cancer type.

Epidemiological Context

Nasopharyngeal cancer (NPC) [2]:

  • China accounts for 46.8% of global cases (approximately 60,000 new cases in 2020)
  • Southern China and Hong Kong ASIR 20-30/100K — more than 10× global average
  • Hong Kong 2023 male age-standardized incidence rate 10.3/100K

Laryngeal cancer [3]:

  • 2021: 38,905 new cases and 19,799 deaths in China
  • 2.52× growth in incidence and 53.8% growth in mortality compared to 1990
  • ASIR decreased from 1.29/100K in 2004 to 1.14/100K in 2018

Thyroid cancer explosion [4]:

  • 1990-2019: Chinese new case volume grew 289.6%
  • Growth rate since 2016 ranks #1 among top 10 cancers (male +149.8%, female +123.6%)
  • 2022: China accounts for 56.8% of global thyroid cancer cases

Practical implication for international patients: China’s head and neck cancer clinical caseload is enormous, with surgical + radiation + immunotherapy experience density among the world’s highest — especially for NPC and thyroid cancer.

China’s Leading Head and Neck Cancer Centers

Sun Yat-sen University Cancer Center (SYSUCC) Nasopharyngeal Department [1]

  • 148–167 beds
  • Nasopharyngeal cancer global benchmark
  • Led 4 of 6 NCCN nasopharyngeal cancer guideline revisions over 20 years
  • Global NPC patient referral center
  • Admitted to Guangdong’s 25-hospital International Medical Service Pilot 2026

Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS) Head and Neck Surgery [5]

  • 3 wards, 100 beds
  • 2019: 73,000+ outpatients, 6,300+ surgeries
  • National Cancer Center anchored

Fudan University Shanghai Cancer Center Head and Neck Surgery [6]

  • 1.5 wards, 88 beds
  • 2,665 thyroid cancer surgeries in 2012
  • Thyroid cancer 10-year survival rate 92%

Beijing Tongren Hospital Otolaryngology and Head and Neck Surgery [7]

  • National-level ENT center
  • Pioneered laryngeal CO₂ laser minimally invasive surgery + larynx-preserving surgery in China (Huang Zhigang, Fang Jugao teams)
  • Rich Chinese thyroid tumor surgical experience

Shanghai 9th People’s Hospital Oral Maxillofacial-Head and Neck Oncology [8]

  • National Key Academic Discipline
  • 929 free flap procedures in 2018, success rate >98%
  • One of China’s largest microvascular free flap reconstruction centers

Other major centers:

  • Peking University School and Hospital of Stomatology
  • West China Hospital of Stomatology, Sichuan University
  • First Hospital, China Medical University
  • Peking University Cancer Hospital Head and Neck Surgery

Four Major Head and Neck Cancers in China

1. Nasopharyngeal Cancer (NPC) — China is World #1

China’s leading position in global NPC treatment:

IMRT radiation + concurrent chemotherapy [1]:

  • SYSUCC is the global NPC IMRT treatment benchmark
  • 5-year OS commonly >85%
  • Primary NPC SPHIC proton/heavy ion 5-year OS 92.9% (see Article 22)

Immunotherapy — China’s greatest contribution to global NPC treatment [9]:

  • Toripalimab (Tuoyi, Junshi):
    • Chinese domestic PD-1
    • FDA approved 2023 for NPC — first FDA-approved Chinese PD-1
    • JUPITER-02 trial: median PFS 21.4 vs 8.2 months
    • NMPA approved for first-line and subsequent treatment
  • Camrelizumab (CAPTAIN-1st trial) also NMPA approved

Recurrent NPC treatment:

  • Endoscopic nasopharyngectomy (SYSUCC-led research)
  • Proton/heavy ion re-irradiation (SPHIC)
  • Immunotherapy + chemotherapy combinations

For international patients: NPC is one of the most medically valuable reasons to travel to China — the combination of SYSUCC + SPHIC + toripalimab represents the world’s most comprehensive NPC treatment system.

2. Laryngeal Cancer — China Leads in Larynx Preservation

Core treatment capabilities [7]:

  • CO₂ laser minimally invasive partial laryngectomy — pioneered in China by Beijing Tongren’s Huang Zhigang team
  • Larynx-preserving function-preserving surgery — partial laryngectomy + reconstruction preserving voice and swallowing function
  • Advanced laryngeal cancer: induction chemotherapy + concurrent chemoradiation (non-surgical larynx preservation option)
  • Total laryngectomy + esophageal voice reconstruction

Indications:

  • T1-T2 early laryngeal cancer: CO₂ laser first choice
  • T3 advanced: induction chemotherapy + chemoradiation (larynx-preserving) or partial laryngectomy
  • T4 / multiple recurrences: total laryngectomy

Leading centers: Beijing Tongren, CICAMS Head and Neck Surgery, Fudan Cancer Head and Neck Surgery, SYSUCC

3. Oral-Maxillofacial / Oropharyngeal Cancer — Microvascular Free Flap Reconstruction

Core treatment capabilities [8]:

  • Radical resection of tongue cancer, floor of mouth cancer, mandibular tumors + immediate microvascular free flap reconstruction
  • Common flaps: radial forearm flap, anterolateral thigh flap, fibular osteocutaneous flap (mandibular reconstruction), iliac osteomyocutaneous flap
  • Shanghai 9th People’s Hospital 929 free flap procedures in 2018, success rate >98% — international top-tier level
  • TORS (transoral robotic surgery): used for pharyngeal-laryngeal tumors — specific Chinese installation and volume data not publicly available
  • HPV+ oropharyngeal cancer: international trend is de-escalation treatment (reducing chemo/radiation intensity), Chinese domestic authoritative clinical data is limited

Leading centers: Shanghai 9th People’s Hospital (largest oral-maxillofacial-head and neck oncology center in China), CICAMS, SYSUCC, Beijing Stomatology, West China Stomatology

4. Thyroid Cancer — Responding to China’s Surging Incidence

Explosive growth in Chinese thyroid cancer — 56.8% of global cases in 2022 [4] — means extremely high Chinese treatment experience density.

Core treatment capabilities:

  • Total thyroidectomy + neck lymph node dissection: standardized surgery
  • Minimally invasive thyroidectomy: transoral, transaxillary, anterior chest approaches
  • Radiofrequency ablation (RFA) for papillary thyroid microcarcinoma (PTMC) [10]:
    • Chinese multi-center research: complete disappearance rate 79%, recurrence rate 1.5%
    • World’s largest case volume
    • Applicable: PTMC (≤1cm), patients declining surgery
  • Thyroid cancer molecular testing: BRAF V600E, TERT promoter mutations, RET rearrangements, etc.
  • 131I (radioactive iodine) therapy: post-operative adjuvant for differentiated thyroid cancer
  • Targeted therapy: lenvatinib, sorafenib (advanced differentiated); vandetanib, cabozantinib (medullary thyroid cancer); selpercatinib (RET mutation)

Leading centers: Fudan Cancer, Beijing Tongren, CICAMS, PUMCH, Shanghai 9th People’s Hospital

5. Salivary Gland and Sinonasal Tumors

Indications:

  • Parotid gland tumors (pleomorphic adenoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, etc.)
  • Submandibular and sublingual gland tumors
  • Sinonasal tumors (including esthesioneuroblastoma)

Key techniques:

  • Facial nerve-preserving parotidectomy
  • Endoscopic transnasal skull base tumor resection (see Article 33)
  • Complex skull base tumor combined resection + reconstruction

Leading centers: Shanghai 9th People’s Hospital, CICAMS, SYSUCC, Beijing Tiantan (skull base combined), PUMCH

Key Technique: Microvascular Free Flap Reconstruction

Complex head and neck cancer surgery often requires large-scale resection + immediate reconstruction — this is the core technical challenge of head and neck surgery.

Chinese international-level capability:

  • Shanghai 9th People’s Hospital 2018: 929 cases with >98% success rate
  • CICAMS, SYSUCC, West China Stomatology also mature
  • On par with top international centers (MD Anderson, Memorial Sloan Kettering head and neck centers, etc.)

Applicable scenarios:

  • Tongue reconstruction after large tongue resection
  • Fibular flap mandibular bone reconstruction after mandibulectomy
  • Large skin defect repair of floor of mouth, pharynx, face
  • Complex laryngeal reconstruction

Pricing Comparison

Treatment US China Estimate
NPC complete treatment (IMRT + chemotherapy + immunotherapy) $150,000–$300,000 $20,000–$50,000
Laryngeal cancer CO₂ laser larynx-preserving surgery $30,000–$60,000 $5,000–$15,000
Tongue cancer resection + free flap reconstruction $80,000–$150,000 $15,000–$35,000
Total thyroidectomy + neck lymph node dissection $20,000–$50,000 $5,000–$15,000
Thyroid microcarcinoma RFA $5,000–$15,000 $2,000–$5,000
NPC proton/heavy ion therapy (SPHIC) US $100K–$200K ~$43K–$48K (see Article 22)

Core value: Chinese head and neck cancer treatment is approximately 1/5 to 1/10 of US.

Practical Pathway for International Head and Neck Cancer Patients in China

Best-suited international patients:

  1. Nasopharyngeal cancer (primary, recurrent, advanced) — China world #1
  2. Complex oral-maxillofacial tumors requiring free flap reconstruction — Shanghai 9th People’s, CICAMS
  3. Early laryngeal cancer seeking larynx preservation — Tongren Hospital CO₂ laser
  4. Thyroid cancer (especially PTMC) — RFA minimally invasive treatment
  5. Unaffordable home country treatment costs

Typical timeline:

Phase Duration
Pre-travel evaluation + MDT 4–6 weeks (remote)
Arrival + on-site evaluation 1 week
Treatment (plan-dependent) 2–8 weeks
Early follow-up 1–2 weeks

Total time in China: typically 3–10 weeks (NPC concurrent chemoradiation approximately 6–8 weeks; proton/heavy ion 4–6 weeks; thyroid surgery 1–2 weeks)

Common Questions

What’s the greatest value of traveling to China for nasopharyngeal cancer? The world’s largest clinical caseload + SYSUCC leading international guidelines + toripalimab (FDA-approved Chinese domestic PD-1) + SPHIC proton/heavy ion — this is a complete combination no other country can provide.

How do toripalimab and US Keytruda compare for NPC? Both are PD-1. Toripalimab is the first FDA-approved immunotherapy for NPC — JUPITER-02 trial data was the basis for FDA approval. In China, toripalimab is priced substantially below Keytruda (see Article 27).

Does thyroid cancer always require surgery, or can RFA be an option? Depends on specifics:

  • Papillary thyroid microcarcinoma (PTMC, ≤1cm) + low-risk features: RFA or active surveillance may be considered
  • Differentiated thyroid cancer >1cm or with invasion: surgery (total or lobar) is standard
  • Advanced / metastatic / medullary: surgery + targeted therapy

Can patients return to normal life after complex head and neck cancer surgery? Depends on resection scope and reconstruction quality. Free flap reconstruction at China’s top centers (success rate >98%) allows most patients to recover reasonable swallowing, voice, and facial appearance function. Multidisciplinary rehabilitation (speech therapy, swallowing training, psychological support) is key.

Can HPV+ oropharyngeal cancer receive “de-escalation treatment” in China? Chinese domestic standardization of de-escalation treatment is lower than in the West. Recommend following international guidelines (ECOG-3311, etc.) — proactively request this during MDT evaluation in China.

How does international insurance reimbursement work for head and neck cancer treatment in China? Most premium international medical insurance plans cover oncology treatment. The key is to confirm before traveling — including IMRT radiation, targeted drugs, and immunotherapy specific coverage.

Bottom Line

Core value of head and neck cancer treatment in China:

  • Nasopharyngeal cancer world #1 (SYSUCC + SPHIC + FDA-approved Chinese domestic PD-1 toripalimab)
  • Highest thyroid cancer experience density globally (China 56.8% of global cases) + RFA minimally invasive treatment
  • Laryngeal cancer larynx preservation leadership (Tongren Hospital)
  • Microvascular free flap reconstruction internationally leading (Shanghai 9th People’s Hospital 929 cases, success rate >98%)
  • Pricing approximately 1/5 to 1/10 of US

Best-suited international patients for travel to China:

  • Nasopharyngeal cancer (primary, recurrent, advanced)
  • Complex oral-maxillofacial tumors requiring free flap reconstruction
  • Early laryngeal cancer seeking larynx preservation
  • Thyroid cancer (especially PTMC patients seeking RFA)
  • Unaffordable home country treatment costs

Total time in China: 3–10 weeks (plan-dependent)

If you are a head and neck cancer patient, MedCareInChina matches the most appropriate Chinese head and neck cancer center and treatment plan based on your specific diagnosis.

→ Send your case to hello@medcareinchina.com

See Service & Refund Policy and Medical Disclaimer for service boundaries.

Sources

  1. SYSUCC NPC global benchmark — Led 4 of 6 NCCN nasopharyngeal cancer guideline revisions over 20 years. Sources: SYSUCC NPC Department https://sysucc.org.cn/bhk ; https://www.sysucc.org.cn/node/2584
  2. China NPC epidemiology — Accounts for 46.8% of global cases (~60,000 new cases in 2020); Southern China/Hong Kong ASIR 20-30/100K. Source: PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC9961544/
  3. China laryngeal cancer epidemiology — 2021: 38,905 new cases and 19,799 deaths; 2.52× and 53.8% growth respectively vs 1990. Source: PLOS ONE https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0318423
  4. China thyroid cancer surge — 1990-2019 growth of 289.6%; 2022 56.8% of global cases. Source: Frontiers Endocrinology https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1500926/full
  5. CICAMS Head and Neck Surgery — 3 wards, 100 beds, 2019 73,000+ outpatients and 6,300+ surgeries. Source: https://www.cicams.ac.cn/dzb/navigation/tou.html
  6. Fudan Cancer Head and Neck Surgery — 1.5 wards, 88 beds, 2012: 2,665 thyroid cancer surgeries, 10-year survival rate 92%. Source: HaoDF https://www.haodf.com/hospital/468/keshi/4486/jieshao.html
  7. Beijing Tongren Hospital laryngeal preservation — CO₂ laser minimally invasive + larynx-preserving function-preserving surgery pioneered in China (Huang Zhigang, Fang Jugao teams). Source: HaoDF https://www.haodf.com/hospital/3/keshi/195/tuijian-houai.html
  8. Shanghai 9th People’s Hospital free flap — 2018: 929 free flap procedures, success rate >98%. Source: 9th National Key Academic Discipline https://gcp.9hospital.com.cn/3072
  9. Toripalimab NPC FDA 2023 approval — First FDA-approved Chinese PD-1. JUPITER-02 trial mPFS 21.4 vs 8.2 months. Source: NCI https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-toripalimab-nasopharyngeal-cancer
  10. Thyroid microcarcinoma RFA China data — Multi-center research: complete disappearance rate 79%, recurrence rate 1.5%. Source: Frontiers in Oncology https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1422634/full
  11. SPHIC NPC 5-year OS data — Primary 5-year OS 92.9%, recurrent 47%. See Article 22.
  12. International patient pricing comparison — Synthesized from MedBridge, ClinicsOnCall, and other industry platforms + US-side public data.